Company intelligence / Profile preview

IAMA Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Currently conducting a Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of single and multiple doses of IAMA-6 (identifier NCT06300398). As of February 2024, they have successfully dosed the first two cohorts of subjects and started dosing the third cohort.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Evotec (manufacturing drug substance and drug product, managing clinical trials)Claris VenturesThe Sapienza University of Rome

Beyond the preview

Go deeper on IAMA Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IAMA Pharmaceutical.

Explore the full profile